SCHEMBL4930501

SCHEMBL4930501

CCOc1ccc(Nc2c(N)cccc2Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ OPRM1 P35372 1/20 0.49
▸ OPRD1 P41143 1/20 0.49
▸ RAD52 P43351 1/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ SLC2A1 P11166 1/20 0.48
▸ TP53 P04637 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ SYK P43405 1/20 0.43
▸ TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14463434 0.80 MAPT (0.47) MAPTKMT2AKDM4ENPSR1L3MBTL1
SCHEMBL4928718 0.77 KMT2A (0.51) MAPTKMT2AKDM4ENPSR1L3MBTL1
SCHEMBL11901671 0.76 ALDH1A1 (0.50) MAPTKMT2AKDM4EL3MBTL1TP53
SCHEMBL5832931 0.75 MAPT (0.66) MAPTKMT2AKDM4ENPSR1L3MBTL1
SCHEMBL11123242 0.75 KDM4E (0.54) MAPTKMT2AKDM4ENPSR1L3MBTL1
SCHEMBL4931897 0.75 KDM4E (0.50) MAPTKMT2AKDM4ENPSR1NFKB1
SCHEMBL12068731 0.74 RAPGEF4 (0.41) MAPTKMT2AKDM4ENPSR1TP53
SCHEMBL27600070 0.74 NLRP3 (0.41) MAPTKDM4EL3MBTL1POLBRAB9A
SCHEMBL28803791 0.73 TSHR (0.51) RAB9ANPC1TSHR
SCHEMBL9514574 0.73 NQO1 (0.70) MAPTKMT2AKDM4ENPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MAPT 4574/4885KMT2A 1963/4885KDM4E 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback